Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
January 02, 2024 08:00 ET
|
Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
Fastox to present its long-lasting botulinum toxin LAST™ technology at the TOXINS 2022 6th International Conference.
July 05, 2022 07:00 ET
|
Fastox Pharma
Press release Fastox to present its long-lasting botulinum toxin LAST™ technology at the TOXINS 2022 6th International Conference. Lausanne, July 5th, 2022 – Swiss biotech Fastox Pharma will...